Skip to content
  • Kategorier
  • Seneste
  • Etiketter
  • Populære
  • Verden
  • Bruger
  • Grupper
Temaer
  • Light
  • Brite
  • Cerulean
  • Cosmo
  • Flatly
  • Journal
  • Litera
  • Lumen
  • Lux
  • Materia
  • Minty
  • Morph
  • Pulse
  • Sandstone
  • Simplex
  • Sketchy
  • Spacelab
  • United
  • Yeti
  • Zephyr
  • Dark
  • Cyborg
  • Darkly
  • Quartz
  • Slate
  • Solar
  • Superhero
  • Vapor

  • Default (No Skin)
  • No Skin
Kollaps
  1. Debatforum
  2. Kategorier
  3. Genmab
  4. Genmab — April 2024

Genmab — April 2024

Planlagt Fastgjort Låst Flyttet Genmab
759 Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • StockBullS Offline
    StockBullS Offline
    StockBull
    wrote on sidst redigeret af
    #77

    Ja, og kurstriggerne er jo stadig lige om hjørnet, så kursen bør ikke falde ret meget. Har faktisk købt lidt her.

    1 Reply Last reply
    0
    • W Offline
      W Offline
      w
      wrote on sidst redigeret af
      #78

      hvor meget brænder de af cash/year
      ?

      1 Reply Last reply
      0
      • G Offline
        G Offline
        GeorgeBest
        wrote on sidst redigeret af
        #79

        Fra Nordea: Genmab (Hold) – Genmab køber det amerikanske biotekselskab Profoundbio for 1,8 mia. USD Primære aktiver er 3 produkter indenfor ADC ( Antibody–drug conjugate) med det mest udviklede produkt i fase 1/2. Vi kender ikke middelbart Profoundbio så vi må undersøge nærmere. Umiddelbart er vi lidt overraskede og havde forventet, at evt. nye investeringer ville være koncentreret på produkter tættere på markedet da Genmab selv har en del produkter i tidlig fase. Der er ingen ændring til

        1 Reply Last reply
        0
        • JørgenVarnæsJ Offline
          JørgenVarnæsJ Offline
          JørgenVarnæs
          wrote on sidst redigeret af
          #80

          Der er CC kl 1300

          1 Reply Last reply
          0
          • G Offline
            G Offline
            GeorgeBest
            wrote on sidst redigeret af
            #81

            omsætningsguidance men operating cost ventes nu i den øvre ende eller moderat højere end tidligere guidance på 12,4-13,4 mia. DKK. Genmab har ca. 3,5 mia. USD i cash så opkøbet bør kunne rummes uden yderligere gæld eller egenkapital.

            1 Reply Last reply
            0
            • JørgenVarnæsJ Offline
              JørgenVarnæsJ Offline
              JørgenVarnæs
              wrote on sidst redigeret af
              #82

              Er JvdW i virkeligheden Russ Hanneman? https://www.youtube.com/watch?v=BzAdXyPYKQo

              1 Reply Last reply
              0
              • bongobobB Offline
                bongobobB Offline
                bongobob
                wrote on sidst redigeret af
                #83

                En åbning mod Kina. Jan har talt om dette før.
                ”R&D center of innovation in Suzhou, China”.De kører også Clinical trails i Kina

                1 Reply Last reply
                0
                • J Offline
                  J Offline
                  JKY_VH
                  wrote on sidst redigeret af
                  #84

                  Tak for orienteringen GB. Jeg kan se af Børsens artikel at “Rina-S” fik “fast track”-i januar, så helt uden evner er produktet vel ikke?

                  1 Reply Last reply
                  0
                  • E Offline
                    E Offline
                    E_L
                    wrote on sidst redigeret af
                    #85

                    on that fast track - FDA Grants Fast Track Status to Rinatabart Sesutecan for FRα-Expressing Ovarian Cancer https://www.onclive.com/view/fda-grants-fast-track-status-to-rinatabart-sesutecan-for-fr--expressing-ovarian-cancer

                    1 Reply Last reply
                    0
                    • JørgenVarnæsJ Offline
                      JørgenVarnæsJ Offline
                      JørgenVarnæs
                      wrote on sidst redigeret af
                      #86

                      still begs the question - is GEN buying an ADC platform, or a pipeline?

                      1 Reply Last reply
                      0
                      • JørgenVarnæsJ Offline
                        JørgenVarnæsJ Offline
                        JørgenVarnæs
                        wrote on sidst redigeret af
                        #87

                        pfizer bled usd 40b for Seagen to enter that space

                        1 Reply Last reply
                        0
                        • E Offline
                          E Offline
                          E_L
                          wrote on sidst redigeret af
                          #88

                          AACR '24 - New Technologies
                          2050 / 7 - Preclinical characterization of PRO1106, a novel and promising SLITRK6-directed sesutecan ADC - https://www.abstractsonline.com/pp8/#!/20272/presentation/6890

                          1 Reply Last reply
                          0
                          • E Offline
                            E Offline
                            E_L
                            wrote on sidst redigeret af
                            #89

                            AACR '24 - New Therapies
                            6580 - A Novel EGFR x cMET bispecific ADC PRO1286 demonstrated broad antitumor activity and promising tolerability in preclinical models - https://www.abstractsonline.com/pp8/#!/20272/presentation/7457

                            1 Reply Last reply
                            0
                            • E Offline
                              E Offline
                              E_L
                              wrote on sidst redigeret af
                              #90

                              AACR '24 - Late-Breaking Research: Experimental and Molecular Therapeutics 4
                              LB425 / 1 - A tumor microenvironment-targeting CD98-directed ADC confers robust anti-tumor activity in multiple cancers with favorable pharmacokinetics and safety profiles in preclinical models https://www.abstractsonline.com/pp8/#!/20272/presentation/10475

                              1 Reply Last reply
                              0
                              • E Offline
                                E Offline
                                E_L
                                wrote on sidst redigeret af
                                #91

                                still under embargo, not sure if it is Profoundbio

                                1 Reply Last reply
                                0
                                • JørgenVarnæsJ Offline
                                  JørgenVarnæsJ Offline
                                  JørgenVarnæs
                                  wrote on sidst redigeret af
                                  #92

                                  must be profoundbio - if you check the duplicate surnames for the presenters, they all have the same first name letter abbreviation.

                                  1 Reply Last reply
                                  0
                                  • JørgenVarnæsJ Offline
                                    JørgenVarnæsJ Offline
                                    JørgenVarnæs
                                    wrote on sidst redigeret af
                                    #93

                                    I'm no expert in chinese names - but that is too much of a coincidence...

                                    1 Reply Last reply
                                    0
                                    • E Offline
                                      E Offline
                                      E_L
                                      wrote on sidst redigeret af
                                      #94

                                      conference call via https://ir.genmab.com/events/event-details/investor-call-proposed-acquisition-profoundbio

                                      1 Reply Last reply
                                      0
                                      • JørgenVarnæsJ Offline
                                        JørgenVarnæsJ Offline
                                        JørgenVarnæs
                                        wrote on sidst redigeret af
                                        #95

                                        two souls...

                                        1 Reply Last reply
                                        0
                                        • JørgenVarnæsJ Offline
                                          JørgenVarnæsJ Offline
                                          JørgenVarnæs
                                          wrote on sidst redigeret af
                                          #96

                                          seems there is no presentation to go with the CC

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind
                                          Svar
                                          • Svar som emne
                                          Login for at svare
                                          • Ældste til nyeste
                                          • Nyeste til ældste
                                          • Most Votes


                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          Powered by NodeBB Contributors
                                          • First post
                                            Last post
                                          0
                                          • Kategorier
                                          • Seneste
                                          • Etiketter
                                          • Populære
                                          • Verden
                                          • Bruger
                                          • Grupper